Gene delivery technologies for cardiac applications

Gene Therapy

Volumn 19, Issue 6, 2012, Pages 659-669

  Katz, M G ^a,b   Fargnoli, A S ^a,b   Pritchette, L A ^b   Bridges, C R ^a,b  

^a LEVINE CANCER INSTITUTE   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

cardiac gene therapy; heart failure; ischemic heart disease; methods of gene delivery

Indexed keywords

ADENOVIRUS VECTOR; COMPLEMENTARY DNA; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR; VASCULOTROPIN 121; VASCULOTROPIN 165;

CARDIOPULMONARY BYPASS; CARDIOVASCULAR SYSTEM; CORONARY ARTERY DISEASE; CORONARY SINUS; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC MANIPULATION; HEART CATHETERIZATION; HEART FAILURE; HUMAN; ISCHEMIC HEART DISEASE; ISCHEMIC PRECONDITIONING; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; TRANSGENE;

ANIMALS; CORONARY ARTERY DISEASE; DISEASE MODELS, ANIMAL; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEART CATHETERIZATION; HEART FAILURE; HUMANS; INJECTIONS; SWINE; TRANSGENES;

EID: 84862018327     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2012.11     Document Type: Review

References (103)

1. Melo LG, Pachori AS, Gnecchi M, Dzau VJ. Genetic therapies for cardiovascular diseases. Trends Mol Med 2005; 11: 240-250. (Pubitemid 40692314)
2. Quarck R, Holvoet P. Gene therapy approaches for cardiovascular diseases. Curr Gene Ther 2004; 4: 207-223. (Pubitemid 38842623)
3. Hedman M, Hartikainen J, Ylä-Herttuala S. Progress and prospects: hurdles to cardiovascular gene therapy clinical trials. Gene Therapy 2011; 18: 743-749.
4. Ylä-Herttuala S, Markkanen JE, Rissanen TT. Gene therapy for ischemic cardiovascular diseases: some lessons learned from the first clinical trials. Trends Cardiovasc Med 2004; 14: 295-300. (Pubitemid 41110607)
5. Karvinen H, Ylä-Herttuala S. New aspects in vascular gene therapy. Curr Opin Pharmacol 2010; 10: 208-211.
6. Lassaletta AD, Chu LM, Sellke FW. Therapeutic neovascularization for coronary disease: current state and future prospects. Basic Res Cardiol 2011; 106: 897-909.
7. Hajjar RJ, del Monte F, Matsui T, Rosenzweig A. Prospects for gene therapy for heart failure. Circ Res 2000; 86: 616-621. (Pubitemid 30208427)
8. Fargnoli AS, Katz MG, Yarnall C, Sumaroka MV, Stedman H, Rabinowitz JE et al. A Pharmacokinetic analysis of molecular cardiac surgery with recirculation mediated delivery of BARKct gene therapy: developing a quantitative definition of the therapeutic window. J Cardiac Fail 2011; 17: 691-699.
9. Katz MG, Swain JD, Tomasulo CE, Sumaroka M, Fargnoli AS, Bridges CR. Current strategies for myocardial gene delivery. J Mol Cell Cardiol 2011; 50: 766-776.
10. Hinkel R, Trenkwalder T, Kupatt C. Gene therapy for ischemic heart disease. Expert Opin Biol Ther 2011; 11: 723-737.
11. Melo LG, Pachori AS, Kong D, Gnecchi M,Wang K, Pratt RE et al. Gene and cell-based therapies for heart disease. FASEB J 2004; 18: 648-663. (Pubitemid 38451787)
12. Mack CA, Patel SR, Schwarz EA, Zanzonico P, Hahn RT, Ilercil A. Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for VEGF 121 improves myocardial perfusion and function in the ischemic porcine heart. J Thorac Cardiovasc Surg 1998; 115: 168-177. (Pubitemid 28082163)
13. Pä tilä T, Ikonen T, Rutanen J, Ahonen A, Lommi J, Lappalainen K et al. Vascular endothelial growth factor C-induced collateral formation in a model of myocardial ischemia. J Heart Lung Transplant 2006; 25: 206-213. (Pubitemid 43156373)
14. Schwarz ER, Speakman MT, Patterson M, Hale SS, Isner JM, Kedes LH et al. Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor in a myocardial infarction model in the rat-angiogenesis and angioma formation. J Am Coll Cardiol 2000; 35: 1323-1330. (Pubitemid 30206908)
15. Vera Janavel GL, De Lorenzi A, Cortes C, Olea FD, Cabeza Meckert P, Bercovich A et al. Effect of VEGF gene transfer on infarct size, left ventricular function and myocardial perfusion in sheep after two months of coronary artery occlusion. J Gene Med 2011; e-pub ahead of print 26 September 2011; doi:10.1002/jgm.168.
16. Bull DA, Bailey SH, Rentz JJ, Zebrack JS, Lee M, Litwin SE et al. Effect of Terplex/VEGF-165 gene therapy on left ventricular function and structure following myocardial infarction. J Control Release 2003; 93: 175-181. (Pubitemid 37421358)
17. Ferrarini M, Arsic N, Recchia FA, Zentilin L, Zacchigna S, Xu X et al. Adeno-associated virus-mediated transduction of VEGF 165 improves cardiac tissue viability and functional recovery after permanent coronary occlusion in conscious dogs. Circ Res 2006; 98: 954-961.
18. Grossman PM, Han Z, Palasis M, Barry JJ, Lederman RJ. Incomplete retention after direct myocardial injection. Cathet Cardiovasc Interv 2002; 55: 392-397. (Pubitemid 34204886)
19. Ishikawa K, Tilemann L, Fish K, Hajjar RJ. Gene delivery methods in cardiac gene therapy. J Gene Med 2011; 13: 566-572.
20. Lazarous DF, Shou M, Stiber JA, Hodge E, Thirumurti V, Goncalves L et al. Adenoviralmediated gene transfer induces sustained pericardial VEGF expression in dogs: effect on myocardial angiogenesis. Cardiovasc Res 1999; 44: 294-302. (Pubitemid 29474092)
21. Landau C, Jacobs AK, Haudenschild CC. Intrapericardial basic fibroblast growth factor induces myocardial angiogenesis in a rabbit model of chronic ischemia. Am Heart J 1995; 129: 924-931.
22. Kornowski R, Fuchs S, Leon MB et al. Delivery strategies to achieve therapeutic myocardial angiogenesis. Circulation 2000; 101: 454-458. (Pubitemid 30067404)
23. Thirumurti V, Shou M, Hodge E, Concalves L, Epstein SE, Lazarous DF et al. Lack of efficacy of intravenous basic fibroblast growth factor in promoting myocardial angiogenesis. J Am Coll Cardiol 1998; 31: 54A.
24. Lazarous DF, Shou M, Stiber JA, Dadhania DM, Thirumurti V, Hodge E et al. Pharmacodynamics of basic fibroblast growth factor: route of administration myocardial and systemic distribution. Cardiovasc Res 1997; 36: 78-85. (Pubitemid 27463575)
25. Lazarous DF, Scheinowitz M, Shou M, Hodge E, Rajanayagam S, Hunsberger S et al. Effects of chronic systemic administration of basic fibroblast growth factor on collateral development in the canine heart. Circulation 1995; 91: 145-153.
26. Scott NA, Cipolla GD, Ross CE, Dunn B, Martin FH, Samuel JL et al. Identification of a potential role for the adventitia in vascular lesion formation after balloon overstretch injury of porcine coronary arteries. Circulation 1996; 93: 2178-2187. (Pubitemid 26187108)
27. Hiltunen MO, Turunen MP, Turunen AM, Rissanen TT, Laitinen M, Kosma VM et al. Biodistribution of adenoviral vector to nontarget tissues after local in vivo gene transfer to arterial wall using intravascular and periadventitial gene delivery methods. FASEB J 2000; 14: 2230-2236.
28. Dzau VJ, Braun-Dullaeus RC, Sedding DG. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med 2002; 8: 1249-1256. (Pubitemid 35373556)
29. Barath P, Popov A, Dillehay GL, Matos G, McKiernan T. Infiltrator angioplasty balloon catheter. Cathet Cardiovasc Diagn 1997; 41: 333-341.
30. Gaffney MM, Hynes SO, Barry F, O'Brien T. Cardiovascular gene therapy: current status and therapeutic potential. Brit J Pharm 2007; 152: 175-188. (Pubitemid 47517600)
31. Sharif F, Daly K, Crowley J, O'Brien T. Current status of catheter-and stent-based gene therapy. Cardiovasc Res 2004; 64: 208-216. (Pubitemid 39361681)
32. Goldman B, Blanke H, Wolinsky H. Influence of pressure on permeability of normal and diseased muscular arteries to horse-radish peroxide. A new catheter approach. Atherosclerosis 1987; 65: 215-225. (Pubitemid 17073849)
33. Rome JJ, Shayani V, Newmark KD, Farrell S, Lee SW, Virmani R et al. Adenoviral vector mediated gene transfer into sheep arteries using a double balloon catheter. Hum Gene Ther 1994; 5: 1249-1258.
34. Wolinsky H, Thung SN. Use of a perforated balloon catheter to deliver concentrated heparin into the wall of the normal canine artery. J Am Coll Cardiol 1990; 15: 475-481. (Pubitemid 20067509)
35. Flugelman MY, Jaklitsch MT, Newman KD, Casscells W, Bratthauer GL, Dichek DA. Low level in vivo gene transfer into the arterial wall through a perforated balloon catheter. Circulation 1992; 85: 1110-1117.
36. Willard JE, Landau C, Glamann DB, Burns D, Jessen ME, Pirwitz MJ et al. Genetic modification of the vessel wall. Circulation 1994; 89: 2190-2197.
37. Takeshita S, Tsurumi Y, Couffinahl T, Asahara T, Bauters C, Symes J et al. Gene transfer of naked DNA encoding for three isoforms of VEGF stimulates collateral development in vivo. Lab Invest 1996; 75: 487-501. (Pubitemid 26346800)
38. Asahara T, Chen D, Tsurumi Y, Kearney M, Rossow S, Symes J et al. Accelerated restitution of endothelial integrity and endothelium-dependent function after phVEGF165 gene transfer. Circulation 1996; 94: 3291-3302.
39. Numaduchi Y, Okumura K, Harada M, Naruse K, Yamada M, Osanai H et al. Catheterbased prostacyclin synthase gene transfer prevents in-stent restenosis in rabbit atheromatous arteries. Cardiovasc Res 2004; 61: 177-185. (Pubitemid 38056694)
40. Clowes AW, Collazzo RE, Karnovsky MJ. A morphologic and permeability study of luminal smooth muscle cells after arterial injury in the rat. Lab Invest 1978; 39: 141-150. (Pubitemid 8390104)
41. Tahlil O, Brami M, Feldman LJ, Branellec D, Steg PG. The Dispatch catheter as a delivery tool for arterial tool for arterial gene transfer. Cardiovasc Res 1997; 33: 181-187. (Pubitemid 27019113)
42. Pavlides GS, Barath P, Maginas A, Vasilikos V, Cokkinos DV, O'Neill WW. Intramural drug delivery by direct injection within arterial wall: first clinical experience with a novel intracoronary delivery-infiltrator system. Cathet Cardiovasc Diagn 1997; 41: 287-292. (Pubitemid 27283812)
43. Laitinen M, Hartikainen J, Hiltunen MO, Eranen J, Kiviniemi M, Narvanen O et al. Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty. Hum Gene Ther 2000; 11: 263-270. (Pubitemid 30080384)
44. Fishbein I, Chorny M, Levy RJ. Site-specific gene therapy for cardiovascular disease. Curr Opin Drug Discov Devel 2010; 13: 203-213.
45. Sharif F, Hynes SO, McMahon J, Cooney R, Conroy S, Dockery P et al. Gene-eluting stents: comparison of adenoviral and adeno-associated viral gene delivery to the blood vessel wall in vivo. Hum Gene Ther 2006; 17: 741-750. (Pubitemid 44100719)
46. Koren B, Weisz A, Fisher L, Gluzman Z, Preis M, Avramovitch N et al. Efficient transduction and seeding of human endothelial cells into metallic stents using bicistronic pseudo-typed retroviral vectors encoding vascular endothelial growth factor. Cardiovasc Revasc Med 2006; 7: 173-178. (Pubitemid 44292063)
47. Takahashi A, Palmer-Opolski M, Smith RC, Walsh K. Transgene delivery of plasmid DNA to smooth muscle cells and macrophages from a biostable polymer-coated stent. Gene Therapy 2003; 10: 1471-1478. (Pubitemid 36987141)
48. Klugherz BD, Jones PL, Cui X, Chen W, Meneveau NF, DeFelice S et al. Gene delivery from a DNA controlled-release stent in porcine coronary arteries. Nat Biotechnol 2000; 18: 1181-1184.
49. Fishbein I, Alferiev IS, Nyanguile O, Gaster R, Vohs JM, Wong GS et al. Bisphosphonate-mediated gene vector delivery from the metal surfaces of stents. Proc Natl Acad Sci USA 2006; 103: 159-164. (Pubitemid 43076121)
50. Klugherz BD, Song C, DeFelice S, Cui X, Lu Z, Connolly J et al. Gene delivery to pig coronary arteries from stents carrying antibody-tethered adenovirus. Hum Gene Ther 2002; 13: 443-454. (Pubitemid 34251509)
51. Perstein I, Connolly JM, Cui X, Song C, Li Q, Jones PL et al. DNA delivery from an intravascular stent with a denatured collagen-polylactic- polyglycolic acid-controlled release coating: mechanisms of enhanced transfection. Gene Therapy 2003; 10: 1420-1428. (Pubitemid 36987135)
52. Lemos PA, Serruys PW, Sousa JE. Drug-eluting stents: cost versus clinical benefit. Circulation 2003; 107: 3003-3007. (Pubitemid 36758969)
53. Lopez JJ, Laham RJ, Stamler A, Pearlman JD, Bunting S, Kaplan A et al. VEGF administration in chronic myocardial ischemia in pigs. Cardiovasc Res 1998; 40: 272-281. (Pubitemid 28506037)
54. Hariawala MD, Horowitz JR, Esakof D, Sheriff DD, Walter DH, Keyt B et al. VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts. J Surg Res 1996; 63: 77-82. (Pubitemid 26197723)
55. Yang R, Thomas GR, Bunting S, Ko A, Ferrara N, Keyt B et al. Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J Cardiovasc Pharmacol 1996; 27: 838-844. (Pubitemid 26000416)
56. Giordano FJ, Ping P, McKirnan MD, Nozaki S, DeMaria AN, Dillmann WH et al. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med 1996; 2: 534-539. (Pubitemid 26151517)
57. Tevaearai HT, Walton GB, Keys JR, Koch WJ, Eckhart AD. Acute ischemic cardiac dysfunction is attenuated via gene transfer of a peptide inhibitor of the betaadrenergic receptor kinase (betaARK1). J Gene Med 2005; 7: 1172-1177. (Pubitemid 41341187)
58. Battler A, Scheinowitz M, Bor A, Hasdai D, Vered Z, Di Segni E et al. Intracoronary injection of basic fibroblast growth factor enhances angiogenesis in infarcted swine myocardium. J Am Coll Cardiol 1993; 22: 2001-2006. (Pubitemid 23359664)
59. Beeri R, Chaput M, Cuerrero L, Kawase Y, Yosefy C, Abedat S et al. Gene delivery of sarcoplasmic reticulum calcium ATPase inhibits ventricular remodeling in ischemic mitral regurgitation. Circ Heart Fail 2010; 3: 627-634.
60. Mariani JA, Kaye DM. Delivery of gene and cellular therapies for heart disease. J Cardiovasc Transl Res 2010; 3: 417-426.
61. Rajanayagam MA, Shou M, Thirumurti V, Lazarous DF, Quyyumi AA, Goncalves L et al. Intracoronary basic fibroblast growth factor enhances myocardial collateral perfusion in dogs. J Am Coll Cardiol 2000; 35: 519-526. (Pubitemid 30125547)
62. von Degenfeld G, Raake P, Kupatt C, Lebherz C, Hinkel R, Gildehaus FJ et al. Selective pressure-regulated retroinfusion of FGF-2 into the coronary vein enhances regional myocardial blood flow and function in pigs with chronic myocardial ischemia. J Am Coll Cardiol 2003; 42: 1120-1128. (Pubitemid 37108604)
63. Kupatt C, Wichels R, Deiss M, Molnar A, Lebherz C, Raake P et al. Retroinfusion of NFkappaB decoy oligonucleotide extends cardioprotection achieved by CD18 inhibition in a preclinical study of myocardial ischemia and retroinfusion in pigs. Gene Therapy 2002; 9: 518-526. (Pubitemid 34449772)
64. Kupatt C, Hinkel R, Vachenauer R, Horstkotte J, Raake P, Sandler T et al. VEGF165 transfection decreases postischemic NF-kappa B-dependent myocardial reperfusion injury in vivo: role of eNOS phosphorylation. FASEB J 2003; 17: 705-707.
65. McPhee AWJ, Samulski RJ. Gene therapy for cardiomyocytes, a heart beat away. Gene Therapy 2009; 17: 707-708.
66. Vinge LE, Raake PW, Koch WJ. Gene therapy in heart failure. Circ Res 2008; 102: 1458-1470.
67. Katz MG, Fargnoli AS, Tomasulo CE, Pritchette LA, Bridges CR. Model-specific selection of molecular targets for heart failure gene therapy. J Gene Med 2011; 13: 573-586.
68. Leotta E, Patejunas G, Murphy G, Szokol J, McGregor L, Carbray J et al. Gene therapy with adenovirus-mediated myocardial transfer of VEGF 121 improves cardiac performance in a pacing model of congestive heart failure. J Thorac Cardiovasc Surg 2002; 123: 1101-1103.
69. Rengo G, Lymperopoulos A, Zincarelli C, Donniacuo M, Soltys S, Rabinowitz JE et al. Myocardial adeno-associated virus serotype 6-BARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation 2009; 119: 89-98.
70. Wright MJ, Wightman LML, Latchman DS, Marber MS. In vivo myocardial gene transfer:optimization and evaluation of intracoronary gene delivery in vivo. Gene Therapy 2001; 8: 1833-1839. (Pubitemid 34141489)
71. Hajjar RJ, Schmidt U, Matsui T, Guerreno JL, Lee K-H, Gwathmey JK et al. Modulation of ventricular function through gene transfer in vivo. Proc Natl Acad Sci USA 1998; 95: 5251-5256. (Pubitemid 28208584)
72. Kawase Y, Ly HQ, Prunier F, Lebeche D, Shi Y, Jin H et al. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol 2008; 51: 1112-1119. (Pubitemid 351374774)
73. Emani SM, Shah AS, Bowman MK, Emani S, Wilson K, Glower DD et al. Catheterbased intracoronary myocardial adenoviral gene delivery: importance of intraluminal seal and infusion flow rate. Mol Ther 2003; 8: 306-313. (Pubitemid 37062840)
74. Iwanaga Y, Hoshijima M, Gu Y, Iwatabe M, Dieterle T, Ikeda Y et al. Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. J Clin Invest 2004; 113: 727-736. (Pubitemid 38544166)
75. Miyamoto MI, del Monte F, Schmidt U, DiSalvo TS, Kang ZB, Matsui T et al. Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci USA 2000; 97: 793-798. (Pubitemid 30070389)
76. del Monte F, Williams E, Lebeche D, Schmidt U, Rosenzweig A, Gwathmey JK et al. Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure. Circulation 2001; 104: 1424-1429. (Pubitemid 32880157)
77. Lai NC, Roth DM, Gao MH, Tang T, Dalton N, Lay YY et al. Intracoronary adenovirus encoding adenylyl cyclase 6 increases left ventricular function in heart failure. Circulation 2004; 119: 330-336. (Pubitemid 38955502)
78. Rebolledo B, Lai NC, Gao MH, Takahashi T, Roth DM, Baird SM et al. Adenylyl cyclase gene transfer increased function of the failing heart. Hum Gene Ther 2006; 17: 1043-1048. (Pubitemid 46076746)
79. Shah AS, White DC, Emani S, Kypson AP, Lilly RE, Wilson K et al. In vivo ventricular gene delivery of a beta-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction. Circulation 2001; 103: 1311-1316. (Pubitemid 32221357)
80. White DC, Hata JA, Shah AS, Glower DD, Lefkowitz RJ, Koch WJ. Preservation of myocardial beta-adrenergic receptor signaling delays the development of heart failure after myocardial infarction. Proc Natl Acad Sci USA 2000; 97: 5428-5433. (Pubitemid 30313735)
81. Pleger ST, Most P, Boucher M, Soltys S, Chuprun JK, Pleger W et al. Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue. Circulation 2007; 115: 2506-2515. (Pubitemid 46763224)
82. Niwano K, Arai M, Koitabashi N, Watanabe A, Ikeda Y, Miyoshi H et al. Lentiviral vector-mediated SERCA2 gene transfer protects against heart failure and left ventricular remodeling after myocardial infarction in rats. Mol Ther 2008; 16: 1026-1032. (Pubitemid 351737066)
83. Sasano T, McDonald AD, Kikuchi K, Donahue JK. Molecular ablation of ventricular tachycardia after myocardial infarction. Nat Med 2006; 12: 1256-1258. (Pubitemid 44706927)
84. Pleger ST, Shah C, Ksienzyk J, Bekeredjian R, Boekstegers P, Hinkel R et al. Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model. Sci Transl Med 2011; 3: 92ra64.
85. Patten RD, Hall-Porter MR. Small animal models of heart failure. Development of novel therapies, past and present. Circ Heart Fail 2009; 2: 138-144.
86. Kloner RA, Jennings RB. Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: part 1. Circulation 2001; 104: 2981-2989. (Pubitemid 33139113)
87. Kloner RA, Jennings RB. Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: part 2. Circulation 2001; 104: 3158-3167. (Pubitemid 34014074)
88. Bridges CR, Gopal K, Holt DE, Yarnall C, Cole S, Anderson RB et al. Efficient myocyte gene delivery with complete cardiac surgical isolation in situ. J Thorac Cardiovasc Surg 2005; 130: 1364-1370.
89. White JD, Thesier DM, Swain JD, Katz MG, Tomasulo CE, Henderson A et al. Myocardial gene delivery using molecular cardiac surgery with recombinant adeno-associated virus vectors in vivo. Gene Therapy 2011; 18: 546-552.
90. Kaye DM, Preovolos A, Marshall T, Byrne M, Hoshijima M, Hajjar RJ et al. Percutaneous cardiac recirculation-mediated gene transfer of an inhibitory phospholamban peptide reverses advanced heart failure in large animals. J Am Coll Cardiol 2007; 50: 253-260. (Pubitemid 47031573)
91. Byrne MJ, Power JM, Preovolos A, Mariani JA, Hajjar RJ, Kaye DM. Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals. Gene Therapy 2008; 15: 1550-1557.
92. Bridges CR. Recirculating method of cardiac gene delivery should be called 'non-recirculating' method. Gene Therapy 2009; 16: 939-940.
93. Kawase Y, Ladage D, Hajjar RJ. Rescuing the failing heart by targeted gene transfer. J Am Coll Cardiol 2011; 57: 1169-1180.
94. Jones JM, Petrofski JA, Wilson KH, Steenbergen C, Koch WJ, Milano CA. Beta2 adrenoreceptor gene therapy ameliorates left ventricular dysfunction following cardiac surgery. Eur J Cardiothorac Surg 2004; 26: 1161-1168. (Pubitemid 39487463)
95. Lillehei CW, DeWall RA, Gott VL, Varco RL. Direct vision correction of calcific aortic stenosis by means of pump-oxygenator and retrograde coronary sinus perfusion. Dis Chest 1956; 30: 123-132.
96. Boekstegers P, Kupatt C. Current concepts and applications of coronary venous retroinfusion. Basic Res Cardiol 2004; 99: 373-381. (Pubitemid 39462359)
97. Giordano FJ. Retrograde coronary perfusion: a superior route to deliver therapeutics to the heart. J Am Coll Cardiol 2003; 42: 1129-1131. (Pubitemid 37108605)
98. Donahue JK, Kikkawa K, Johns DC, Marban E, Lawrence JH. Ultrarapid, highly efficient viral gene transfer to the heart. Proc Natl Acad Sci USA 1997; 94: 4664-4668. (Pubitemid 27194300)
99. Logeart D, Hatem SN, Heimburger M, Roux AL, Michel JB, Mercadier JJ. How to optimize in vivo gene transfer to cardiac myocytes: mechanical or pharmacological procedures? Hum Gene Ther 2001; 12: 1601-1610. (Pubitemid 32911731)
100. Fearon WF, Ikedo F, Bailey PR, Hiatt BL, Herity NA, Carter AJ et al. Evaluation of highpressure retrograde coronary coronary venous delivery of FGF-2 protein. Catheter Cardiovasc Interv 2004; 61: 422-428. (Pubitemid 38298286)
101. Rapti K, Chaanine AH, Hajjar RJ. Targeted gene therapy for the treatment of heart failure. Can J Cardiol 2011; 27: 265-283.
102. Wasala NB, Shin J-H, Duan D. The evolution of heart gene delivery vectors. J Gene Med 2011; 13: 557-565.
103. Katz MG, Swain JD, Fargnoli AS, Bridges CR. Gene therapy during cardiac surgery: role of surgical technique to minimize collateral organ gene expression. Interact Cardiovasc Thorac Surg 2010; 11: 727-731.